Tilray | TRLY - Cash And Equivalent


Tilray reported $264.83M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 16.86M 3.14M Sep/2025
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Avita Medical AUD 10.24M 1.98M Dec/2025
Canopy Growth CAD 371.32M 73.26M Dec/2025
Cronos Group USD 791.79M 7.62M Dec/2025
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Divis Laboratories Ltd INR 4.15B 31.87B Mar/2025
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Moderna USD 1.91B 687M Mar/2026
Organigram Holdings CAD 7.58M 20.62M Dec/2025
Organon & Co USD 1.12B 542M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Tilray USD 264.83M 43.16M Jun/2025
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026
Zealand Pharma A/S 4.58B 1.4B Dec/2025